Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUCAR-B68 in Relapsed/Refractory Multiple Myeloma
NCT05498545Phase 1Terminated
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Nov 2022
- Primary completion
- May 2025
- Modality
- CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LUCAR-B68 in multiple myeloma (MM), sponsored by Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Incidence, severity, and type of treatment-emergent adverse events at 2 years, Dose-limiting toxicity rate at 2 years and 3 more. Started Nov 2022; status: terminated.
02
Drugs
LUCAR-B68
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05498545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05498545.